Connect with us

Technology

JOYY Reports First Quarter 2026 Financial Results: Total Revenue Up 12.4% YoY, Substantially Expanding Shareholder Returns

Published

on

SINGAPORE, May 25, 2026 /PRNewswire/ — JOYY Inc. (NASDAQ: JOYY) (“JOYY” or the “Company”), a leading global technology company, today announced its unaudited financial results for the first quarter ended March 31, 2026.

In the first quarter, JOYY’s globally diversified ecosystem continued to take shape, with its three business pillars—social entertainment, advertising, and e-commerce—bolstering one another in a self-reinforcing strategic flywheel. The Company’s total revenues for the quarter grew 12.4% year over year to US$555.7 million, the highest year-over-year growth rate the Company has delivered in recent years. Social entertainment revenue was US$400.4 million, up 3.2% year over year, while the Company’s second growth engine, BIGO Ads ad tech and SHOPLINE e-commerce, continued to scale with strong momentum. BIGO Ads contributed US$124.8 million, up 55.6% year over year, while SHOPLINE revenue increased 16.1% year over year to US$30.5 million. In the first quarter, non-GAAP[1] operating income and non-GAAP[1] EBITDA came in at US$38.0 million and US$45.7 million, up 22.5% and 13.2% year over year, respectively. Operating cash inflow for the quarter was US$46.0 million.

Simultaneously, JOYY announced a new share repurchase program, under which the Company is authorized to repurchase up to US$600 million of its shares until the end of 2028, and a new quarterly dividend program, under which a total of approximately US$900 million in cash will be distributed on a quarterly basis between 2026 and 2028. The new shareholder return program, totaling US$1.5 billion, represents a significant increase compared to the previous program (US$900 million)  announced in 2025. From January 1 to May 22, 2026, JOYY had returned a total of US$156.8 million to shareholders through US$87.9 million in share repurchases and US$68.9 million in dividends, under its 2025 program.

Ms. Ting Li, Chairperson and Chief Executive Officer of JOYY, commented, “We delivered a strong start to 2026. Total revenues for the first quarter reached US$555.7 million, up by 12.4% year over year, our strongest year-over-year growth rate in recent years. This quarter marks the first time we are reporting results under our new three-segment structure: Social Entertainment, BIGO Ads, and SHOPLINE. Our AI-driven globally diversified ecosystem is taking shape with social entertainment, advertising, and e-commerce reinforcing one another in a powerful strategic flywheel. With AI serving as the backbone of our entire operations—driving content recommendation, advertising efficiency, and merchant intelligence across all three segments—our business pillars form a closed-loop system that deepens our competitive moat and drives long-term value creation for JOYY and our shareholders.”

First Quarter 2026 Financial Highlights

Net revenues in the first quarter of 2026 were US$555.7 million, representing an increase of 12.4% from US$494.4 million in the first quarter of 2025.

– Social Entertainment revenue increased by 3.2% to US$400.4 million from US$387.8 million in the first quarter of 2025.

– BIGO Ads revenue increased by 55.6% to US$124.8 million from US$80.2 million in the first quarter of 2025.

– SHOPLINE revenue increased by 16.1% to US$30.5 million from US$26.3 million in the first quarter of 2025.

Operating income was US$6.8 million.
 Non-GAAP[1] operating income was US$38.0 million, representing an increase of 22.5% from US$31.0 million in the first quarter of 2025.

Non-GAAP[1] EBITDA was US$45.7 million, representing an increase of 13.2% from US$40.4 million in the first quarter of 2025.

Net cash as of March 31, 2026 was US$3,175.1 million.

Net cash from operating activities was US$46.0 million.

First Quarter 2026 Business Highlights

Social Entertainment Business

In the first quarter, global average mobile MAUs reached 276.3 million, up 6.1% year over year and 1.5% quarter over quarter. Social entertainment revenue increased by 3.2% year over year to US$400.4 million, with livestreaming revenue up 2.4% year over year. Core livestreaming paying users grew 5.9% year over year.

For flagship product Bigo Live, the Company improved its streamer incentive structure, launched targeted support programs for high-quality content categories, and integrated new AI capabilities. These initiatives drove ongoing gains in both content engagement and payment conversion. Number of active streamers increased 1.5% quarter over quarter, and average effective streaming hours per streamer rose 1.4% quarter over quarter. The Company has now fully rolled out AI smart tools for streamers across core markets, meaningfully improving interaction efficiency. In April, AI-generated interactive virtual gifts accounted for 34% of total virtual gift consumption on Bigo Live.

On the operating side, Bigo Live successfully hosted BIGO Awards Gala 2026 in South Korea along with regional galas in countries including Indonesia and the Philippines during the first quarter. These events underscore Bigo Live’s continued commitment to recognizing creator excellence, strengthening regional creator ecosystems, and connecting diverse communities worldwide. Bigo Live continued to pursue content innovation and successfully launched the inaugural BIGO Content Award in North America, drawing over 300 top-tier, highly active streamers to drive measurable growth in DAUs and user retention. Additionally, Bigo Live launched a Ramadan-themed initiative featuring a digital revival of traditional content, which drove user engagement during a key cultural period and reinforced its capability to deliver scalable and localized content experiences across diverse markets.

BIGO Ads Advertising Technology Business

In the first quarter, broader traffic coverage, multi-vertical advertiser expansion, and ongoing algorithm optimization fueled the growth momentum of JOYY’s ad tech business. BIGO Ads generated US$124.8 million in advertising revenue, up 55.6% year over year, with third-party Audience Network ad revenue delivering 78.8% year-over-year growth.

On the supply side, SDK traffic maintained strong growth, up 109% year over year in the first quarter. On the demand side, the Company’s strategic presence across multiple verticals drove an enrichment of its advertiser mix and enhanced ecosystem density. This multi-vertical approach not only accelerated data accumulation and algorithmic iteration, but also strengthened its traffic bidding capabilities. Notably, web-based demand grew 90% year over year and delivered positive sequential growth, while IAA demand sustained 97% year-over-year growth. Geographically, BIGO Ads continued to prioritize high-value developed markets. North America remains its largest market, while Western Europe delivered notable momentum, with revenue up 27% quarter over quarter.

On the algorithm side, BIGO Ads is steadily and prudently scaling its computing infrastructure and strengthening its R&D talent base. By integrating data feedback from advertisers across channels and leveraging the dual growth of traffic scale and advertiser density, BIGO Ads has built a rich behavioral data layer. This enables multi-dimensional, precise user profiling and real-time model iteration, which in turn improves ad delivery efficiency.

SHOPLINE E-Commerce Business

In the first quarter, SHOPLINE delivered strong results. Revenue was US$30.5 million, up 16.1% year over year, with gross margin expanding further to 51.5%. Revenue growth from cross-border merchants remained robust, sustaining over 60% year-over-year growth. This is the first quarter the Company is reporting SHOPLINE as a standalone segment, underscoring the Company’s diversified growth.

As global commerce enters the omnichannel era, merchants increasingly desire autonomy and full-funnel data ownership. The Company is building SHOPLINE as an AI-native, one-stop omnichannel commerce infrastructure that offers merchants a fully open and connectable retail operating system. Through deep integration of payment, logistics, and marketing modules, SHOPLINE empowers merchants across every stage of their journey, from store setup and transactions to fulfillment and full-lifecycle customer retention.

SHOPLINE is accelerating the integration of a suite of AI-powered capabilities. These tools will drive SHOPLINE’s evolution from an enablement tool to an AI-driven commerce engine. AI-powered traffic allocation and automated decision-making will unlock new growth opportunities and new levels of precision across omnichannel retail.

This press release includes certain non-GAAP financial measures as additional clarifying items to aid investors in further understanding the Company’s performance and the impact that these items and events had on the financial results. The non-GAAP financial measures provided above should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP. For details of the non-GAAP measures, including the reconciliations of GAAP measures to non-GAAP measures, please refer to the press release titled “JOYY Reports First Quarter 2026 Unaudited Financial Results” issued by the Company on May 26, 2026.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/joyy-reports-first-quarter-2026-financial-results-total-revenue-up-12-4-yoy-substantially-expanding-shareholder-returns-302781403.html

SOURCE JOYY Inc.

Continue Reading

Technology

Leo Cancer Care Brings Into Clinical Use an Upright Radiotherapy Platform Cleared for Use With Any Radiation Beam

Published

on

By

Upright. From Concept to Clinical Reality

BOSTON, Sept. 27, 2026 /PRNewswire/ — Leo Cancer Care is marking a defining moment for radiation oncology as upright radiotherapy moves from concept to clinical reality.

The Upright Platform is designed to be beam-agnostic and cleared for integration with both particle- and photon-compatible fixed-beam technologies, offering health networks unprecedented choice rather than being restricted to one beam manufacturer or treatment configuration.

A Flexible, Now Clinically Available Platform Built for the Future

Following the first clinical treatment using Leo Cancer Care’s Marie® upright patient positioning and imaging system in June 2026, patients can now receive radiotherapy in an upright position. Enabled by a partnership with Mevion Medical System, utilising their compact, fixed-beam proton accelerator and powered by RayStation®, the treatment planning system from RaySearch Laboratories.

While this represents an important clinical milestone, the potential of Leo Cancer Care’s upright technology extends beyond one installation or treatment configuration. Its flexible platform creates opportunities for clinicians and technology partners to explore compliant IGRT system combinations around the needs of their patients, infrastructure and services.

Expanding Access to Upright Photon Radiotherapy

While Leo Cancer Care’s initial product offering, the Marie® solution, is 510(k) cleared and CE marked  to be integrated with any fixed beam, including conventional photon therapy, the company revealed development of a dedicated fixed-beam photon platform of its own (subject to regulatory clearance), at ASTRO 2025. This platform would integrate upright patient positioning, imaging and a fixed photon beam. Treating with photons in the upright position has the potential to offer greater patient choice while enabling more compact radiotherapy solutions that could help expand access to high-quality cancer care.

This next future innovation represents an important step towards bringing upright positioning and imaging into conventional radiotherapy and changing how photon treatment services are designed and delivered. This new method is already being utilized in new proton therapy installations where health networks are adopting a treatment delivery solution that was not so long ago widely questioned.

One Upright Environment. One Consistent Workflow. A Single Source of Truth.

Leo Cancer Care has taken a fundamentally different approach to radiotherapy. The radiation beam remains fixed while the patient is positioned upright and slowly rotated to multiple beam angles, enabling radiation to be delivered around the target area to deliver their personalised treatment plan.

At the heart of the solution is the upright platform, connecting fan beam imaging, planning, positioning and treatment delivery around a single patient position. Because the patient is imaged in the position they are treated in, every stage of the pathway works from the same geometry, giving the clinical team one reference point to plan and verify against.

For patients, upright radiotherapy provides a treatment experience centred around a more natural position, with eye-to-eye interaction with the clinical team. It may be particularly valuable for people who find it difficult or uncomfortable to lie flat because of breathing difficulties, pain, mobility challenges or anxiety.

International research also suggests that upright positioning may support more consistent anatomical positioning and reduce organ motion for certain treatment sites. These potential benefits will continue to be investigated as more upright systems enter research and clinical use.

From Innovation to Adoption

Stephen Towe, Co-Founder and CEO of Leo Cancer Care said: “The first clinical treatment using our technology proved that upright radiotherapy is no longer simply an idea for the future. It is now a clinical reality. This milestone is only the beginning. By connecting imaging, planning, positioning and treatment delivery in the upright position, we can create a single source of truth throughout the patient’s treatment journey. Our beam-agnostic approach gives us the flexibility to work with different compatible fixed-beam technologies, helping reduce the infrastructure traditionally associated with advanced radiotherapy and supporting our ambition to expand access to high-quality cancer care.”

At the American Society for Radiation Oncology’s 2026 Annual Meeting in Boston, Leo Cancer Care will share its clinical progress and vision for the future.

The next phase will focus on building clinical evidence, supporting further installations and collaborating with healthcare and technology partners to make advanced treatment more human and accessible.

Natural anatomy. New possibilities. Think Upright.

View original content to download multimedia:https://www.prnewswire.com/news-releases/leo-cancer-care-brings-into-clinical-use-an-upright-radiotherapy-platform-cleared-for-use-with-any-radiation-beam-302890849.html

SOURCE Leo Cancer Care

Continue Reading

Technology

Fuse Oncology to Showcase S!GNAL Workflow Experience at ASTRO 2026

Published

on

By

Potential workflow illustrates how patient workflow coordination in GE HealthCare’s Intelligent Radiation Therapy™ (iRT) software solution could connect to targeted charge review in S!GNAL

BOONE, N.C., Sept. 27, 2026 /PRNewswire/ — Fuse Oncology today announced plans to showcase a potential workflow experience with GE HealthCare’s Intelligent Radiation Therapy™ (iRT) software solution at the ASTRO 2026 Annual Meeting. The concept illustrates how iRT could launch S!GNAL, Fuse Oncology’s charge capture solution, from the patient workflow using patient information. This could provide users a direct path from workflow coordination in iRT to targeted charge review in S!GNAL while preserving patient context and reducing manual handoffs between systems.

Radiation oncology teams often work across multiple systems that rarely connect, such as EMR, OIS, treatment planning, and billing systems. iRT is an AI-supported software solution for radiation therapy workflow management designed to connect tools, coordinate workflows, and reduce manual handoffs to help patients progress from diagnosis to treatment more efficiently. The potential experience with S!GNAL illustrates how that coordinated workflow could extend to targeted charge review, a capability planned for a future iRT release.

Charge capture in radiation oncology is a distributed problem. A missing IGRT image, an untagged physics consult, or an inconsistent weekly treatment management charge typically comes to light weeks after the service, once the clinical context has gone cold. Correcting it means revisiting old records, reconstructing physician intent, and coordinating between clinical and billing teams — and that is only for the errors that surface at all.

S!GNAL reviews charge data daily and flags missed or miscoded charges within 24 hours of service, rather than surfacing them in a retrospective audit weeks later. Its rule logic covers every category of radiation oncology code, including the ones that carry the most impact: missed treatment fractions, weekly physics, weekly treatment management, and dosimetry planning. S!GNAL evaluates planning charges against the discrete data in the treatment planning system rather than inferring them from a document’s name or a predetermined template, then uses natural language processing to check those expectations against what the clinical documents say. In a multi-site organization S!GNAL is installed once and configured separately for each location, so a freestanding clinic and a hospital-based department are each reviewed against the rules that apply to them.

In a deployment across 15 sites of an 18-site radiation oncology network, S!GNAL surfaced $1,092,202 in missed treatment delivery and IGRT charges between July 2024 and March 2025, each identified within 24 hours of service. Charge lag fell by more than 30 days.

“Every clinic we talk to has the same problem, and almost none of them have the staff to solve it by auditing harder. The fix is to put the detection where the work already happens, in the system the team is already in. Every hour a billing or clinical team spends chasing last month is an hour not spent moving a patient toward treatment,” said James Bauler, Chief Executive Officer, Fuse Oncology.

The potential workflow experience is planned to be shown during the ASTRO 2026 exhibit dates, September 27 to 29 in Boston. Fuse Oncology will be at booth 2533. The capability is currently being developed and evaluated for potential future commercial availability, with further details to be announced at a later date.

About Fuse Oncology

Fuse Oncology is a healthcare technology company focused on radiation oncology, delivering the operational layer for the clinical and administrative workflow. Fuse delivers SaaS solutions that break down healthcare workflow and data silos to create a seamless experience for clinicians. By placing the broader electronic medical record system at the center of the architecture, Fuse eliminates duplicative and inefficient efforts to enable a future where oncology care moves at the speed of patients. For more information, visit FuseOnc.com. Stay updated on our latest developments by following us on LinkedIn @fuseoncology.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fuse-oncology-to-showcase-sgnal-workflow-experience-at-astro-2026-302890548.html

SOURCE Fuse Oncology, Inc.

Continue Reading

Technology

Best Prescription Sunglasses (2026): Quay Featured Among Stylish, Fashion-Forward RX Frames for Everyday Wear and Versatile Personal Style by Consumer365

Published

on

By

NEW YORK, Sept. 27, 2026 /PRNewswire/ — Consumer365 has recognized Quay in a 2026 feature examining the best prescription sunglasses for everyday wear and versatile personal style. The coverage highlights prescription-ready fashion frames, varied lens options, and published prices relevant to shoppers seeking premium-looking eyewear within a defined budget.

Best Prescription Sunglasses:

Quay – offers prescription-ready sunglasses with fashion-focused frames, customizable lens tints, and adjustable or built-in nose pads, combining premium-looking designs with everyday versatility and personal style.

The feature focuses on Quay’s online prescription sunglasses collection. The range includes aviators, squares, rounds, and cat eyes, supported by filters for frame size and bridge fit. The selection allows different silhouettes to be considered alongside practical requirements for vision correction, comfort, and daily use.

Consumer365’s assessment draws on published product specifications and ordering guidance. The coverage examines accessible luxury as a styling approach, with attention to frame proportions, finishes, and customization. The review also explains why the complete prescription configuration matters when evaluating price and suitability.

Prescription Frames With Distinct Design Details

The featured collection includes several interpretations of contemporary prescription eyewear. Three models illustrate how frame shape, construction, and bridge design create different styling options:

GONE VIRAL RX: A small oval aviator combines metal construction with an integrated hinge and a clean temple design. The narrow-fit frame uses adjustable silicone nose pads and provides slightly smaller coverage.WIRED RX: An oversized unisex square features rounded corners, lightweight construction, and built-in nose pads. The softened outline gives the frame a relaxed profile for everyday styling.AURA POINTS RX: A narrow oval frame combines standard arms with built-in nose pads. Published measurements include a 141 mm frame width and a 35 mm lens height, creating a compact visual profile.

Each featured model includes a hard case and cleaning cloth. Together, the designs demonstrate how prescription-ready frames can vary in material, scale, bridge support, and overall silhouette.

Premium-Looking Eyewear and Budget Considerations

At the time of research, Quay‘s US product pages displayed AURA POINTS RX at $75, WIRED RX at $85, and GONE VIRAL RX at $175. The figures provide reference points for browsing. The displayed amounts should not be treated as guaranteed totals for every prescription configuration.

Lens material and selected options can affect the completed purchase. A meaningful budget assessment therefore considers the full frame-and-lens configuration. Comparing models at the same prescription settings provides a clearer basis for evaluating value.

The different displayed prices show that Quay’s prescription collection covers more than one price level. AURA POINTS RX and WIRED RX provide lower starting points, while GONE VIRAL RX sits at a higher listed price. Selection can therefore depend on silhouette, frame material, bridge fit, and preferred finish, subject to the final lens configuration.

The accessible-luxury angle centers on appearance rather than a claim of luxury-grade construction. Metallic accents, tortoise patterns, and considered proportions contribute to a polished look. Consumer365’s feature separates those visual qualities from measurable considerations such as prescription compatibility and frame dimensions.

Lens Materials and Sun Tint Options

Quay‘s featured RX pages list single-vision polycarbonate, 1.67 high-index, and 1.74 ultra-high-index lens options. Published specifications identify anti-reflective coating, scratch resistance, and 100% UVA/UVB protection across the listed choices. Blue light filtering is also available as an optional add-on. Availability should be confirmed for the selected frame and prescription.

Sunglass tint options include Black Fade, Brown Gradient, Smoke Solid, Green, and Navy. Light Blue, Pink, and Purple provide further color choices. Lens tint can change the appearance of a frame without changing the underlying silhouette.

Quay notes that prescription lens colors may differ slightly from their nonprescription versions. Product photographs should be considered alongside the selected prescription tint before an order is completed.

Quay’s prescription guidance identifies polarization as an available sunglass option for polycarbonate and 1.67 high-index lenses. Tint selection and polarization should be reviewed separately during configuration, rather than assumed to be interchangeable features.

Prescription strength can influence the finished appearance, but Quay’s prescription lenses use an aspherical design that helps keep them on the thinner side. Frame size and lens material can still affect the final profile. Guidance from an optical professional can help assess lens material and frame proportions together, supporting a configuration that accommodates both the prescription and the intended style.

Fit and Prescription Requirements

Published measurements provide a practical starting point for comparing frames. WIRED RX lists a 144 mm frame width, an 18 mm bridge, and 148 mm temples. Comparing those dimensions with a comfortable existing pair can help narrow the selection.

Virtual try-on appears on the featured product pages. The tool supports visual comparisons but cannot establish physical comfort during extended wear. Quay’s fitting guidance recommends matching frame width to face width and avoiding pressure around the nose, ears, and cheekbones.

Online purchases require an unexpired eyeglass prescription and pupillary distance. Contact lens prescriptions cannot be used to order prescription glasses. Pupillary distance helps position the lenses appropriately relative to the eyes.

Quay currently offers single-vision prescription glasses and sunglasses online. Progressive lenses are available through select stores and authorized dealers. The ordering route therefore depends on the required lens type, alongside the chosen frame and prescription details.

Ordering and Everyday Ownership

Quay advises allowing up to three weeks for completed prescription orders. Custom production can require up to two weeks before shipping confirmation. Planning around the prescription timeline is relevant when eyewear is needed for travel or another scheduled occasion.

Online prescription purchases are generally final sale. Limited remake provisions apply, including a complimentary lens remake when a doctor updates or revises a prescription. Requests must be made within 30 days of delivery and require supporting documentation.

Quay recommends cleaning lenses with a microfiber cloth and lens cleaner. Product guidance advises against using paper towels or clothing. The included case provides storage between wears.

Consumer365’s recognition brings attention to Quay’s combination of prescription-ready designs and configurable sun lenses. The feature encourages evaluation of appearance, fit, prescription requirements, and complete pricing together, providing a practical framework for selecting eyewear suited to everyday use.

The full review is available at the Consumer365 website.

About Quay

Quay is a global eyewear brand offering a wide selection of sunglasses and prescription glasses. The company’s collections emphasize contemporary design, functional lens features, and pricing that remains accessible to a broad range of consumers. Quay products are available through its direct-to-consumer website, Quay stores and select retail partners worldwide.

About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided.

View original content:https://www.prnewswire.com/news-releases/best-prescription-sunglasses-2026-quay-featured-among-stylish-fashion-forward-rx-frames-for-everyday-wear-and-versatile-personal-style-by-consumer365-302890245.html

SOURCE Consumer365.org

Continue Reading

Trending